Full Press Release Details
IDEAYA Biosciences Announces IND Clearance for Werner Helicase Development Candidate IDE275 GSK959 for a Phase 1 Study in MSI High Solid Tumors.
IDYA
IDEAYA Biosciences Announces IND Clearance for Werner Helicase Development Candidate IDE275 GSK959 for a Phase 1 Study in MSI High Solid Tumors
Key Takeaway: IDEAYA Biosciences Announces IND Clearance for Werner Helicase Development Candidate IDE275 GSK959 for a Phase 1 Study in MSI High Solid Tumors
Price reaction · baseline $29.3 (2024-10-25 close) · clean, no other IDYA news in the window
day 0 close · peak
+2.4%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma